|
195 Companies |
|
327 Products |
|
327 Products |
|
167 Mechanisms of Action |
|
13 Trials |
|
3266 News |
|
| «12...56575859606162636465666768» |
- Alhemo (concizumab) / Novo Nordisk
New P1 trial: Investigation of the Pharmacokinetics of NNC172-2021, at Two Different Dose Levels, in Healthy Japanese Subjects (clinicaltrials.gov) - Mar 13, 2012
P1, N=8, Completed, Sponsor: Novo Nordisk
- ganetespib (ADX-1612) / Aldeyra
Enrollment open: A Phase I Study of Ganetespib +/- Bortezomib in Patients With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov) - Mar 13, 2012
P1, N=15, Recruiting, Sponsor: Emory University
Not yet recruiting --> Recruiting
- Trial completion, HEOR: Caregiver Support in the Quality of Life of Patients Who Are Undergoing Donor Bone Marrow Transplantation (clinicaltrials.gov) - Mar 12, 2012
P=N/A, N=168, Completed, Sponsor: Case Comprehensive Cancer Center
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||| Kogenate FS (octocog alfa sucrose formulation) / CSL Behring, Bayer
Trial completion: EffeKt Taiwan- Efficacy and Safety of Long-term Treatment With KOGENATE (clinicaltrials.gov) - Mar 12, 2012
P=N/A, N=82, Completed, Sponsor: Bayer
Active, not recruiting --> Completed Recruiting --> Completed
- | Kogenate FS (octocog alfa sucrose formulation) / CSL Behring, Bayer
Trial completion, Surgery: Non-interventional Observation of Practical Implementation, Efficacy and Safety of Continuous Infusion With KOGENATE Bayer in Surgery (clinicaltrials.gov) - Mar 12, 2012
P=N/A, N=26, Completed, Sponsor: Bayer
Recruiting --> Completed Recruiting --> Completed
- Sylvant (siltuximab) / Jazz
Enrollment change: A Study Evaluating the Effects of Siltuximab on the Heart in Patients With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma (clinicaltrials.gov) - Mar 11, 2012
P1, N=30, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Recruiting --> Completed N=25 --> 30
- Sylvant (siltuximab) / Jazz
Enrollment closed: A Study Evaluating the Effects of Siltuximab on the Heart in Patients With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma (clinicaltrials.gov) - Mar 11, 2012
P1, N=30, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
N=25 --> 30 Recruiting --> Active, not recruiting
- fresolimumab (GC 1008) / Sanofi
Enrollment change: Anti-TGF-beta Therapy in Patients With Myelofibrosis (clinicaltrials.gov) - Mar 7, 2012
P1, N=3, Completed, Sponsor: John Mascarenhas
Recruiting --> Active, not recruiting N=14 --> 3
- Kepivance (palifermin) / SOBI, Amgen, peripheral blood stem cell transplantation / National Cancer Institute
Enrollment change: Melphalan and Palifermin in Treating Patients Undergoing An Autologous Peripheral Stem Cell Transplant for Stage II or III Multiple Myeloma (clinicaltrials.gov) - Mar 7, 2012
P1, N=38, Completed, Sponsor: Barbara Ann Karmanos Cancer Institute
N=14 --> 3 N=30 --> 38
- Farydak (panobinostat) / Secura Bio
Clinical: Study of the Combination of Panobinostat & Carfilzomib in Patients With Relapsed &/or Refractory Multiple Myeloma (clinicaltrials.gov) - Mar 7, 2012
P1, N=36, Recruiting, Sponsor: Emory University
- ||| Doptelet (avatrombopag) / SOBI
Trial completion: Subject Variability in Two Lots of E5501 Administered to Fed and Fasted Healthy Subjects (clinicaltrials.gov) - Mar 7, 2012
P1, N=84, Completed, Sponsor: Eisai Inc.
N=30 --> 38 Recruiting --> Completed
- | ATryn (antithrombin) / LFB Biotechnologies, Knight Therap
New P4 trial, Surgery: Response of Recombinant Antithrombin in Heparin Resistant Patients Undergoing Cardiac Surgery (clinicaltrials.gov) - Mar 6, 2012
P4, N=60, Suspended, Sponsor: Mayo Clinic
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen, Mozobil (plerixafor) / Sanofi
New P2 trial: Collection of Transplant Stem Cells for Plasma Cell Myeloma (clinicaltrials.gov) - Mar 6, 2012
P2, N=70, Recruiting, Sponsor: National Cancer Institute (NCI)
- | Enrollment open: RETIC Trial: Reversal of Trauma Induced Coagulopathy Using Coagulation Factor Concentrates or Fresh Frozen Plasma (clinicaltrials.gov) - Mar 6, 2012
P3, N=200, Recruiting, Sponsor: Medical University Innsbruck
Recruiting --> Completed Not yet recruiting --> Recruiting
- | allogeneic Myeloma GM-CSF Vaccine / Sidney Kimmel Comprehensive Cancer Center, BMS, Novartis
Trial initiation date: Allogeneic GM-CSF Vaccine and Lenalidomide in Treating Myeloma Patients With Near Complete Remission (clinicaltrials.gov) - Mar 6, 2012
P2, N=15, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Not yet recruiting --> Recruiting Initiation date: Jun 2011 --> Jan 2012
- bortezomib / Generic mfg.
New P2 trial: Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment (clinicaltrials.gov) - Mar 6, 2012
P2, N=20, Terminated, Sponsor: University of Iowa
- | Doptelet (avatrombopag) / SOBI
New P1 trial: A Study in Healthy Subjects to Evaluate Bioavailability of 4 Formulations of E5501 (clinicaltrials.gov) - Mar 6, 2012
P1, N=28, Completed, Sponsor: Eisai Inc.
- | allogeneic Myeloma GM-CSF Vaccine / Sidney Kimmel Comprehensive Cancer Center, BMS, Novartis
Enrollment open: Allogeneic GM-CSF Vaccine and Lenalidomide in Treating Myeloma Patients With Near Complete Remission (clinicaltrials.gov) - Mar 6, 2012
P2, N=15, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Initiation date: Jun 2011 --> Jan 2012 Not yet recruiting --> Recruiting
- Trial completion: T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies (clinicaltrials.gov) - Mar 6, 2012
P1, N=20, Completed, Sponsor: National Institutes of Health Clinical Center (CC)
Not yet recruiting --> Recruiting Recruiting --> Completed
- Trial completion: Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation (clinicaltrials.gov) - Mar 6, 2012
P1/2, N=0, Completed, Sponsor: National Institutes of Health Clinical Center (CC)
Recruiting --> Completed Active, not recruiting --> Completed
- || New P3 trial: RETIC Trial: Reversal of Trauma Induced Coagulopathy Using Coagulation Factor Concentrates or Fresh Frozen Plasma (clinicaltrials.gov) - Mar 5, 2012
P3, N=200, Recruiting, Sponsor: Medical University Innsbruck
- ||||| New P2 trial: Clinical Study of Lyophilized Plasma in Patients With Liver Disease (clinicaltrials.gov) - Mar 5, 2012
P2, N=100, Not yet recruiting, Sponsor: HemCon Medical Technologies, Inc
- Trial termination: Nutritional Treatment of Overweight Adolescents With Cardiovascular Risk Factors (PowerUp) (clinicaltrials.gov) - Mar 5, 2012
P=N/A, N=27, Terminated, Sponsor: Children's Hospital Boston
Active, not recruiting --> Completed Recruiting --> Terminated; Inadequate enrollment and lack of funds.
- Enrollment change: Nutritional Treatment of Overweight Adolescents With Cardiovascular Risk Factors (PowerUp) (clinicaltrials.gov) - Mar 5, 2012
P=N/A, N=27, Terminated, Sponsor: Children's Hospital Boston
Recruiting --> Terminated; Inadequate enrollment and lack of funds. N=46 --> 27
- || New P3 trial: PROPPR: Pragmatic, Randomized Optimal Platelet and Plasma Ratios (clinicaltrials.gov) - Mar 4, 2012
P3, N=680, Completed, Sponsor: The University of Texas Health Science Center, Houston
- | Trial completion: Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications (clinicaltrials.gov) - Mar 4, 2012
P3, N=1337, Completed, Sponsor: Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
N=46 --> 27 Active, not recruiting --> Completed
- Rituxan (rituximab) / Roche
Trial initiation date: Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant (clinicaltrials.gov) - Mar 1, 2012
P2, N=3, Terminated, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed Initiation date: Sep 2011 --> May 2012
- ||| Stimuvax (tecemotide) / EMD Serono, Ono Pharma
Enrollment open: EMR 63325-011: Common Safety Follow-up Trial of Tecemotide (L-BLP25) (clinicaltrials.gov) - Feb 28, 2012
P=N/A, N=250, Enrolling by invitation, Sponsor: Merck KGaA
Initiation date: Sep 2011 --> May 2012 Not yet recruiting --> Enrolling by invitation
- Pegasys (pegylated interferon ? -2a) / Roche
Enrollment open: MPD-RC 111: Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET) (clinicaltrials.gov) - Feb 28, 2012
P2, N=188, Recruiting, Sponsor: Ronald Hoffman
Not yet recruiting --> Enrolling by invitation Not yet recruiting --> Recruiting
- melphalan / Generic mfg.
Enrollment closed, Metastases: Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon Alfa in Treating Patients With Advanced Multiple Myeloma (clinicaltrials.gov) - Feb 28, 2012
P2, N=40, Active, not recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Not yet recruiting --> Recruiting Completed --> Active, not recruiting
- busulfan / Generic mfg.
Trial termination: Busulfan in Multiple Myeloma (clinicaltrials.gov) - Feb 26, 2012
P1/2, N=13, Terminated, Sponsor: Guido Tricot
Completed --> Active, not recruiting Recruiting --> Terminated; PI left the institution
- Empliciti (elotuzumab) / AbbVie, BMS
Trial initiation date: A Phase 1/2, Multi-center, Open-label, Dose-escalation Study of Elotuzumab(Humanized Anti-CS1 Monoclonal IgG1 Antibody) and Bortezomib in Subjects With Multiple Myeloma Following One to Three Prior Therapies. (clinicaltrials.gov) - Feb 26, 2012
P1/2, N=28, Terminated, Sponsor: Abbott
Recruiting --> Terminated; PI left the institution Initiation date: Oct 2007 --> May 2008
- busulfan / Generic mfg.
Enrollment change: Busulfan in Multiple Myeloma (clinicaltrials.gov) - Feb 26, 2012
P1/2, N=13, Terminated, Sponsor: Guido Tricot
Initiation date: Oct 2007 --> May 2008 N=50 --> 13
- |||||||||| New P3 trial: Velcade (Bortezomib) Consolidation After Transplant (clinicaltrials.gov) - Feb 23, 2012
P3, N=220, Recruiting, Sponsor: Janssen Scientific Affairs, LLC
- Enrollment open: Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies (clinicaltrials.gov) - Feb 23, 2012
P1, N=18, Recruiting, Sponsor: Robert Lowsky
N=50 --> 13 Not yet recruiting --> Recruiting
- bortezomib / Generic mfg.
Enrollment closed: Tandem Transplantation in Multiple Myeloma (MM) Patients With <12 Months of Prior Treatment (clinicaltrials.gov) - Feb 23, 2012
P2, N=204, Active, not recruiting, Sponsor: Guido Tricot
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | Trial completion: The Safety of Autologous Lyophilized Plasma Versus Fresh Frozen Plasma in Healthy Volunteers (clinicaltrials.gov) - Feb 22, 2012
P1, N=16, Completed, Sponsor: HemCon Medical Technologies, Inc
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- BMS-936559 / BMS
Trial withdrawal: Safety Study of Anti-Programmed Death-Ligand 1 in Hematologic Malignancy (clinicaltrials.gov) - Feb 21, 2012
P1, N=0, Withdrawn, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Completed Not yet recruiting --> Withdrawn
- BMS-936559 / BMS
Enrollment change: Safety Study of Anti-Programmed Death-Ligand 1 in Hematologic Malignancy (clinicaltrials.gov) - Feb 21, 2012
P1, N=0, Withdrawn, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Withdrawn N=110 --> 0
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Enrollment change: Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer (clinicaltrials.gov) - Feb 21, 2012
P2, N=32, Completed, Sponsor: City of Hope Medical Center
N=110 --> 0 N=60 --> 32
- || Nuwiq (simoctocog alfa) / Octapharma
Trial completion: Efficacy and Safety Study of Human-cl rhFVIII in PTPs With Severe Hemophilia A (clinicaltrials.gov) - Feb 21, 2012
P3, N=32, Completed, Sponsor: Octapharma
N=60 --> 32 Active, not recruiting --> Completed
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Trial completion: Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer (clinicaltrials.gov) - Feb 21, 2012
P2, N=32, Completed, Sponsor: City of Hope Medical Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| Clinical: Comparison of Rapid Thrombelastography and Conventional Coagulation Testing for Haemostatic Resuscitation in Trauma (clinicaltrials.gov) - Feb 20, 2012
P=N/A, N=120, Recruiting, Sponsor: Denver Health and Hospital Authority
- || Zolinza (vorinostat) / Merck (MSD)
Clinical: Myeloma XI: Use of Thalidomide, Lenalidomide, Carfilzomib, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma Patients (clinicaltrials.gov) - Feb 20, 2012
P3, N=1970, Recruiting, Sponsor: University of Leeds
- Promacta (eltrombopag) / Novartis
Enrollment open: Promacta Pregnancy Registry (clinicaltrials.gov) - Feb 19, 2012
P=N/A, N=1, Recruiting, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Active, not recruiting --> Recruiting
- Promacta (eltrombopag) / Novartis
Trial initiation date: Eltrombopag for Thrombocytopenia in Patients With Relapsed Multiple Myeloma (clinicaltrials.gov) - Feb 19, 2012
P2, N=24, Recruiting, Sponsor: Dana-Farber Cancer Institute
Active, not recruiting --> Recruiting Initiation date: Jan 2012 --> Apr 2012
- Zolinza (vorinostat) / Merck (MSD)
Trial initiation date, Combination therapy: Study of Vorinostat With Doxil and Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - Feb 18, 2012
P2, N=0, Withdrawn, Sponsor: UNC Lineberger Comprehensive Cancer Center
Initiation date: Jan 2012 --> Apr 2012 Initiation date: Jan 2012 --> Apr 2012
- fludarabine IV / Generic mfg., busulfan / Generic mfg.
Enrollment closed: Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease (clinicaltrials.gov) - Feb 18, 2012
P2, N=70, Active, not recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
Initiation date: Jan 2012 --> Apr 2012 Recruiting --> Active, not recruiting
- Clinical: Non Neutralizing Antibodies: Prevalence and Characterization (clinicaltrials.gov) - Feb 16, 2012
P=N/A, N=300, Recruiting, Sponsor: University Hospital, Montpellier
- Arzerra (ofatumumab) / Novartis, Genmab
New P2 trial: Ofatumumab and Bortezomib in Treating Patients With Previously Untreated Waldenstrom Macroglobulinemia (clinicaltrials.gov) - Feb 16, 2012
P2, N=3, Active, not recruiting, Sponsor: Roswell Park Cancer Institute